GreyScan

GreyScan is an Australian private company developing portable trace-detection instruments based on Capillary Zone Electrophoresis (CZE). The company commercialized its ETD-100 and ETD-100L devices for inorganic explosive detection and has extended the same core platform into pharmaceutical cleaning verification and infectious-disease detection applications. Its healthcare-relevant products include the PTD-1 for pharmaceutical trace detection and TVD programs aimed at SARS-CoV-2 and other pathogen detection. GreyScan appears to operate primarily as a device and platform company rather than a therapeutics developer, with commercial activity in security/forensics and adjacent expansion into pharma manufacturing and diagnostics. The business was formed in 2015 in Melbourne and has collaborated closely with the University of Tasmania on development and commercialization of its underlying technology.